Tumor Genomic Profiling denied as experimental or investigational by Avalon Healthcare Solutions?
An experimental denial requires the appeal to cite the FDA approval (if any), peer-reviewed phase III data, and the recognised specialty-society guideline that supports the treatment for your indication.
US health-plan appeal rights
Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules
Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.
What Avalon Healthcare Solutions typically requires
Avalon manages genetic/molecular testing UM for many BCBS plans. Tumor profiling per NCCN biomarker recommendations.
What works in the appeal
Confirm Avalon network status — reroute to in-network lab if denial is purely contractual. NCCN biomarker testing recommendations require panel-based testing (NSCLC: EGFR/ALK/ROS1/BRAF/KRAS/MET/RET/NTRK/ERBB2/PD-L1). ACOG #226 (2020) — cfDNA offered to all pregnancies.
The Avalon Healthcare Solutions angle on Tumor Genomic Profiling
## Why Avalon Healthcare Solutions Denied Tumor Genomic Profiling as "Experimental" — and How to Appeal
Avalon Healthcare Solutions manages specialty and genomic benefit programs for many health plans and applies its own clinical coverage policies to determine what is "established" versus "investigational." A denial calling comprehensive tumor genomic profiling (CGP) "experimental" or "investigational" typically reflects a policy determination that the evidence base does not yet meet the plan's internal standard for coverage — but this determination is frequently out of step with mainstream oncology practice and is regularly overturned on appeal. Tumor genomic profiling is endorsed by major oncology guideline bodies for specific cancer types and situations, and FDA-authorized tests exist for this purpose.
## Why This Denial Is Frequently Overturned
The "experimental" label is a coverage decision, not a medical fact, and it is subject to challenge. When a test is FDA-authorized (either approved or cleared) and is recommended by a recognized clinical guideline organization (such as NCCN) for the patient's specific cancer type, the experimental classification is difficult to sustain on external review. Many state insurance laws also require coverage of routine costs associated with FDA-authorized cancer tests recommended in widely recognized compendium guidelines.
## Federal and State Appeal Framework
Under ACA Section 2719, non-grandfathered plans must provide internal appeal rights and access to independent external review. ERISA Section 503 governs employer-sponsored plans. External review must generally be requested within approximately four months of a final internal denial. Expedited review is available when delay would seriously jeopardize health — this almost always applies in active oncology cases. Some states have enacted cancer clinical trial or genomic-testing coverage mandates that may apply independently of the federal appeal process.
## What to Gather Before You Appeal
- Avalon's published clinical coverage policy for tumor genomic profiling. Download it directly from Avalon's or the plan's website. Identify the specific language used to call the test experimental and the criteria that would lift that designation.
- FDA authorization documentation. If the ordered test uses an FDA-approved or cleared platform (e.g., an FDA-approved companion diagnostic or lab-developed test with de novo authorization), document that. FDA authorization is powerful evidence against an experimental label.
- Treating oncologist's medical-necessity letter. The oncologist should: (a) identify the patient's specific cancer type and stage; (b) cite the applicable NCCN guideline category for CGP in this indication (generically — do not cite specific version numbers or recommendation grades, but reference that the guideline body endorses the test); (c) explain how the test results would directly guide treatment selection; and (d) assert that this is standard of care, not experimental.
- Published clinical society statements. Your oncologist may reference that major oncology societies recognize CGP as part of standard workup for certain advanced or rare cancers.
## Criteria-Mapping Structure
| Avalon's experimental criteria | Your evidence | Document | |---|---|---| | No FDA authorization | FDA clearance/approval of test platform | FDA database printout | | Not in recognized guidelines | NCCN category for this cancer type | Oncologist letter | | No proven clinical utility | Treatment selection rationale | Oncologist letter + chart |
## Timeline
Request expedited review immediately in oncology cases. Include all documentation in the first submission. If Avalon's internal reviewer is a non-oncologist, request that the appeal be reviewed by a board-certified oncologist with relevant subspecialty expertise — this is your right under most external review standards.
Next steps
- Find the date on the denial letter — your appeal window starts there.
- Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
- Request the insurer's claim file in writing — they must provide it.
- Submit your appeal in writing with new clinical evidence and a physician statement.
Get the letter drafted
DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.
Start my appeal — $30 with code SEO25 →